Printed Cornea Tissue Restores Sight in Israeli Medical Breakthrough

Arie Bat, founder of the company Saysse Bio, has achieved a significant breakthrough in regenerative medicine by successfully implanting lab-grown and 3D-printed cornea tissue into patients, restoring their vision. Initially met with skepticism and even ridicule, Bat's vision of creating functional human tissue for transplantation has now been validated. "People said it was impossible, that it was science fiction," Bat stated, "So we proved that it is no longer science fiction. There are people who couldn't see and now they see thanks to this technology."

The pivotal moment occurred on October 29, 2025, when a team led by Professor Michael Mimouni at Rambam Health Care Campus, along with Professor David Zadok from Shaare Zedek Medical Center and Professor Eitan Livny from Beilinson Hospital, performed the world's first successful implantation of a bio-printed, cell-based corneal graft. The patient, who had been blind in the treated eye, regained sight post-surgery. This marked the first time a functional, living-cell-based corneal implant created through bioprinting was used in a human.

Since then, the ongoing Phase 1 open-label trial has included five patients, with plans to enroll up to 15. The primary goals are to assess safety and tolerability, with preliminary efficacy indicators also being monitored. Full trial results are expected in 2027. While referred to as a "printed cornea," the implant specifically replaces the endothelium, a vital cell layer responsible for maintaining corneal transparency, along with a collagen-based support layer. This addresses a critical need, as over half of current cornea transplants involve replacing this specific layer.

Saysse Bio's technology offers a potential solution to the global shortage of donor corneas, where an estimated 15 million people lack access to sight-restoring treatments. The company can reportedly generate 400 to 500 implants from a single donor cornea by isolating and multiplying cells in the lab, a significant increase from the one-to-one ratio of current practices. Bat also noted that the printed implants exhibit a higher density of endothelial cells, potentially leading to longer functionality, though this requires further long-term study.

Bat, a physicist with a background in the defense industry, co-founded Saysse Bio in 2015 with Professor Anthony Atala and Professor Shai Suker. The company's "four-dimensional printing" process involves isolating, culturing, and multiplying cells before printing and a subsequent "maturation" phase where cells integrate to form functional tissue. This on-demand production aims to eliminate the uncertainty of waiting for donor tissue, ensuring availability when needed. The manufacturing process adheres to strict sterile conditions and quality control measures.